ARTICLE | Top Story

Almirall, Forest in LABA deal

December 18, 2009 2:30 AM UTC

Almirall S.A. (Madrid:ALM) partnered with Forest Laboratories Inc. (NYSE:FRX) to develop and commercialize Almirall's LAS100977 in the U.S. The once-daily long-acting adrenergic receptor beta 2 agonist (LABA) is in Phase II testing to treat asthma and chronic obstructive pulmonary disease (COPD). The companies plan to develop the compound in combination with an undisclosed corticosteroid using Almirall's Genuair multi-dose dry powder inhaler. Forest is responsible for regulatory submissions and commercialization in the U.S. Almirall will receive $75 million up front and is eligible for undisclosed milestones and royalties. ...